*Vol-3 Issue-2 2025*
*Scientific Research Journal of Medical and Health Science*
ISSN: 2584-1521, Peer Reviewed Journal

# Quelling HIV: Enduring Antiretroviral Potency Amidst Initial Viremia and Its Absence

Lulu Adam, Student, Epidemiology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Walter Tenga, Lecture, Epidemiology, Kilimanjaro Christian Medical University College, Moshi, Tanzania

**Abstract**

*When it comes to viremia, or measurable viral levels in the bloodstream, the Human Immunodeficiency Virus (HIV) remains a major concern for world health. Despite the revolutionary impact of antiretroviral medication (ART), obstacles to adherence, viral reservoirs, and resistant virus strains continue to pose a threat to HIV treatment. Whether or not initial viremia is present, this article investigates the long-term efficacy of antiretroviral therapy. Our research delves at the inner workings of the virus, how long-acting antiretroviral therapy (ART) affects patients, and possible approaches to attaining long-term viral suppression. Examining the current literature critically reveals new information on viral reservoirs, medicines that improve adherence, and changing treatment paradigms.*

***Keywords***: *HIV viremia, Antiretroviral therapy (ART), Long-acting antiretroviral therapy (LA-ART), Cabotegravir and rilpivirine, Viral reservoirs, Drug resistance, Treatment adherence, Virologic suppression, Injectable HIV therapy, HIV management strategies*

---

## 1. Introduction

According to the HIV-CAUSAL Collaboration et al. (2010), the introduction of combination antiretroviral therapy (cART) has completely changed the way HIV is treated. It has greatly decreased death and morbidity rates and turned HIV into a chronic illness that can be managed. Problems still exist, however, and this is especially true when viremia (HIV-positive blood levels) persists even after strict ART adherence. Virus reservoirs, immune system dynamics, and adherence issues are common causes of persistent viremia, which makes it difficult to completely suppress the virus (Halvas et al., 2020).

The persistence of long-lived CD4+ T-cell clones that may maintain viral production even when on antiretroviral therapy (ART) is a major concern in HIV treatment. These big T-cell clones were shown to be a significant cause of chronic viremia by Halvas et al. (2020), suggesting that the virus may not be completely eradicated by traditional ART. Because of this, there is an urgent need for new treatment methods that specifically target dormant viral reservoirs and boost the effectiveness of current treatments. Adherence to daily ART is another crucial component impacting treatment results. Inconsistent medicine consumption may lead to viremia and an increased chance of resistance, despite the fact that typical oral regimens need careful adherence to maintain viral suppression (Chen et al., 2023). Real-world obstacles include socioeconomic hurdles, shame, and pill weariness. A solution to these problems is the rise of long-acting injectable medications like rilpivirine and cabotegravir, which may be administered once every 24 hours and help with adherence and viral suppression (Swindells et al., 2020).

Whether or not initial viremia is present, this article investigates the long-term efficacy of antiretroviral

therapy. Our goal is to provide light on how antiretroviral therapy (ART) may be fine-tuned to combat HIV and guarantee long-term suppression by studying the processes of viral persistence, the effects of long-acting ART, and potential future treatment approaches.

## 2. HIV Viremia and the Challenge of ART Suppression

Despite the remarkable success of antiretroviral therapy (ART) in controlling HIV, certain patients experience persistent viremia, where detectable levels of the virus remain despite treatment. This challenge is primarily driven by viral reservoirs and barriers to adherence, both of which pose significant obstacles to achieving complete viral suppression. Understanding these challenges is crucial for optimizing treatment strategies and improving long-term outcomes for people living with HIV.

### 2.1 Persistent Viremia Despite ART

While ART is designed to suppress viral replication to undetectable levels, some individuals continue to experience persistent viremia. One of the key reasons for this is the presence of latent viral reservoirs within long-lived CD4+ T cells. Halvas et al. (2020) identified large T-cell clones that actively produce infectious virus despite ART, making complete viral eradication difficult. These viral reservoirs serve as a hidden source of HIV, reactivating under certain conditions and leading to ongoing viral replication even in patients who adhere to their ART regimen.

Additionally, viremia can result from low-level replication in anatomical sanctuaries, such as lymphoid tissues, where ART penetration may be suboptimal. These findings suggest that while ART effectively suppresses HIV replication in most cases, it does not eliminate the virus entirely. This underscores the need for novel strategies, such as latency-reversing agents, immune-based therapies, and intensified ART regimens, to target and reduce these persistent viral reservoirs.

### 2.2 Barriers to Adherence and Viral Suppression

To keep the virus at bay and avoid medication resistance, ART adherence is key. Consistent adherence, however, might be difficult due to many structural, social, and economic obstacles. Treatment gaps may occur for a variety of reasons, including but not limited to: stigma, drug abuse, mental illness, poverty, and inaccessibility to healthcare. One of the biggest worries in HIV care is non-adherence, which may lead to virologic failure, medication resistance, and the spread of HIV.
To overcome these obstacles, new therapeutic approaches including long-acting antiretroviral therapy (LA-ART) have emerged. Based on their projections, Chen et al. (2023) found that LA-ART might alleviate the daily pill-taking burden significantly, which could help those with adherence challenges. A possible answer is injectable formulations like rilpivirine and cabotegravir, which guarantee maintained medication levels and reduce the likelihood of missed doses. These treatments have the potential to significantly improve long-term health outcomes for HIV patients by decreasing viremia and adherence-related difficulties.

## 3. Long-Acting Antiretroviral Therapy: A Game-Changer?

A game-changer in HIV treatment, long-acting antiretroviral therapy (LA-ART) tackles drug adherence, a long-standing problem in disease management. Strict daily adherence is necessary to sustain viral suppression with traditional oral ART. Many patients, however, have trouble sticking to their regimens for many reasons, including pill tiredness, stigma, financial limitations, mental health issues, and insecure housing (Chen et al., 2023). As an alternative, long-acting injectable ART formulations may be administered less often, which may result in more consistent viral suppression and an overall better quality of life for HIV-positive individuals.

Intramuscular injections of cabotegravir and rilpivirine given monthly or every other month constitute one of the more encouraging LA-ART regimens. Clinical studies have shown that this regimen is just as effective as daily oral ART in keeping the virus at bay, if not more so (Swindells et al., 2020). People who have trouble sticking to their treatment plans, whether because of housing instability, mental illness, or a lack of access to healthcare, may benefit from LA-ART because of its ability to increase adherence (Davis et al., 2024).

### 3.1 The Role of Cabotegravir and Rilpivirine

The long-acting injectable formulations of cabotegravir and rilpivirine, two inhibitors of integrase strand transfer and non-nucleoside reverse transcriptase, respectively, have been created to allow longer drug release. This eliminates the need for oral medication and allows for long-term suppression of the virus. When taken correctly, this combination has shown to be quite successful in sustaining HIV suppression, according to clinical studies.

In a groundbreaking trial, Swindells et al. (2020) shown that patients who had previously attained virologic control were able to sustain viral suppression with monthly injections of cabotegravir and rilpivirine. Most individuals maintained undetectable viral loads throughout the trial period, highlighting the high levels of effectiveness associated with adherence to the injection schedule, according to the research. This provides support for the idea that switching to a long-acting injectable regimen might be a viable option to daily pill-taking for those who have suppressed their HIV using oral ART.

Extending these results, Orkin et al. (2020) showed that long-acting ART was efficacious even after an oral induction phase. After a few weeks of taking cabotegravir and rilpivirine orally, trial participants switched to injectable forms of the medication. Patients were able to test their medicine tolerance in a controlled environment before beginning the long-acting regimen. This method increased the viability of long-acting ART in larger groups by improving adherence and minimising the risk of early virologic failure, according to the research.

People who have trouble sticking to daily regimens should have easier access to long-acting formulations, according to Davis et al. (2024). Their findings support the idea that LA-ART might be a useful public health tool in the fight against HIV/AIDS by increasing the number of people who successfully complete treatment and decreasing the number of new infections among those who face economic and structural obstacles to receiving care.

Although cabotegravir and rilpivirine are long-acting antiretroviral therapy options, their effectiveness is contingent upon healthcare infrastructure that supports punctual injection schedules, patient education, and correct execution. Adherence to injection appointments is crucial since missed doses might result in inadequate medication levels, which in turn increases the risk of drug resistance and viral resurgence.

### 3.2 Impact on Drug Resistance and Treatment Outcomes

Although long-acting ART offers a practical answer to problems with adherence, it also poses new concerns, most notably with drug resistance. Missed injections in a LA-ART regimen may lead to lengthy periods of poor drug exposure, in contrast to oral ART where missing doses can usually be remedied by

continuing therapy. This gives HIV the chance to evolve and become resistant to the drugs it is given, which might make future treatments less effective.

Timely intervention in instances of treatment failure considerably improved virologic results, according to Paton et al. (2014), who investigated the effect of drug resistance in second-line ART regimens among African populations. They concluded that strict procedures of monitoring and follow-up are necessary for the efficacy of long-acting ART in ensuring that patients take their injections at the prescribed intervals. To further avoid the development of resistance, backup strategies, including oral bridging regimens, should be thought of in the event that injections are missed.

In situations with low resources, the problem of medication resistance becomes even more pressing since the healthcare system may not be able to provide constant availability to injections. The development of patient education programs, community-based administration, and mobile injectable clinics are all necessary steps towards the widespread implementation of LA-ART. Furthermore, in groups where drug resistance is already prevalent, further studies are required to ascertain the long-term consequences of LA-ART on resistance patterns.

The length of time that viral suppression with LA-ART lasts is another aspect that impacts therapy results. Additional evidence is required to determine the effectiveness of cabotegravir and rilpivirine in patients with persistent viral loads, however preliminary trials have shown that both medications sustain suppression in patients with virological control. To find out whether LA-ART can be extended to patients who have never had therapy or have a history of viral failure, answering this question is essential.

## 4. Future Directions and Clinical Implications

With the continued evolution of HIV treatment, integrating long-acting ART into mainstream clinical practice is a promising step forward. However, further research is needed to address:

- The long-term impact of long-acting ART on viral reservoirs.
- Strategies for early identification of non-responders to prevent resistance development.
- The feasibility of expanding access to long-acting ART in resource-limited settings.

The findings from current studies suggest that a combination of traditional and novel ART strategies will be essential for achieving sustained viral suppression. Expanding research efforts in understanding viral latency and immune responses could also pave the way for future HIV cure strategies.

## 5. Conclusion

Long-acting antiretroviral therapy (LA-ART) has emerged as a promising strategy to address persistent viremia and adherence-related challenges in HIV treatment. By offering sustained drug release through injectable formulations, LA-ART reduces reliance on daily medication, improving adherence and long-term viral suppression. However, challenges such as drug resistance, missed doses, and accessibility in resource-limited settings must be carefully managed. Research has demonstrated that cabotegravir and rilpivirine effectively maintain virologic control, yet continued monitoring is essential to prevent resistance development. Expanding patient access to LA-ART requires robust healthcare infrastructure, community-based administration, and contingency plans for missed injections. Future investigations should focus on optimizing LA-ART for treatment-naïve individuals and those with persistent viremia. Addressing viral

reservoirs remains crucial for achieving complete HIV eradication. Integrating innovative treatment strategies alongside traditional ART will be key to ensuring long-term disease control. With continued advancements, LA-ART has the potential to revolutionize HIV management and improve patient outcomes worldwide.

**Reference :**


- Halvas EK, Joseph KW, Brandt LD, Guo S, Sobolewski MD, Jacobs JL, Tumiotto C, Bui JK, Cyktor JC, Keele BF, Morse GD, Bale MJ, Shao W, Kearney MF, Coffin JM, Rausch JW, Wu X, Hughes SH, Mellors JW. HIV-1 viremia is not suppressible by antiretroviral therapy, and it can originate from large T cell clones that produce the infectious virus. J Clin Invest. 2020 Nov 2;130(11):5847-5857. doi: 10.1172/JCI138099. PMID: 33016926; PMCID: PMC7598056.
- Chen W, Gandhi M, Sax PE, Neilan AM, Garland WH, Wilkin T, Cohen R, Ciaranello AL, Kulkarni SP, Eron J, Freedberg KA, Hyle EP. Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers. Open Forum Infect Dis. 2023 Jul 22;10(8):ofad390. doi: 10.1093/ofid/ofad390. PMID: 37601728; PMCID: PMC10439527.
- HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JAC, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123–37.
- Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020; 382:1112–23.
- Jennifer M Davis, Aadia Rana, Paul E Sax, Sara H Bares, Long-Acting Cabotegravir Plus Rilpivirine in People With Human Immunodeficiency Virus With Adherence Challenges and Viremia: Current Data and Future Directions, Clinical Infectious Diseases, 2024;, ciae557, https://doi.org/10.1093/cid/ciae557
- Orkin C, Arasteh K, Hernandez-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124-1135. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1909512
- Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234-247. Available at: https://pubmed.ncbi.nlm.nih.gov/25014688.